patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_505743 | REC_0010801 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.8 | 72 | female | 2 | 24 | 5.5 | 1 | entrectinib 600 mg daily | 25.2 | false | MSS | 2026-03-15T05:35:59.554312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647338 | REC_0010802 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.9 | 61 | male | 0 | 4 | 5.1 | 7 | alectinib 600 mg BID | 18.7 | true | MSS | 2026-03-15T05:35:59.554589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311210 | REC_0010803 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 11.9 | 63 | female | 1 | 12 | 7.8 | 1 | entrectinib 600 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:59.554854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357647 | REC_0010804 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 14.1 | 73 | female | 1 | 9 | 3.2 | 1 | osimertinib 80 mg daily | 7.2 | true | MSS | 2026-03-15T05:35:59.555291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_369758 | REC_0010805 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 13.7 | 77 | female | 2 | 19 | 2.6 | 5 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:59.555607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255987 | REC_0010806 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 8 | 56 | female | 1 | 9 | 6 | 4 | pembrolizumab 200 mg q3w | 4.2 | true | MSS | 2026-03-15T05:35:59.555880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782483 | REC_0010807 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 3.4 | 82 | female | 0 | 44 | 5 | 2 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:35:59.556244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888470 | REC_0010808 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.9 | 68 | female | 0 | 24 | 3.6 | 4 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:35:59.556554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_906906 | REC_0010809 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 10.6 | 60 | female | 0 | 14 | 2.8 | 2 | osimertinib 80 mg daily | 26 | true | MSS | 2026-03-15T05:35:59.556908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519720 | REC_0010810 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 11.5 | 64 | male | 1 | 9 | 7.4 | 2 | pembrolizumab 200 mg q3w | 20.4 | false | MSS | 2026-03-15T05:35:59.557236+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652405 | REC_0010811 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 16.9 | 67 | female | 1 | 10 | 7 | 1 | alectinib 600 mg BID | 28.8 | true | MSS | 2026-03-15T05:35:59.557484+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616067 | REC_0010812 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.2 | 82 | male | 3 | 15 | 5.6 | 6 | alectinib 600 mg BID | 11.5 | false | MSS | 2026-03-15T05:35:59.557745+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412962 | REC_0010813 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 6.4 | 57 | male | 0 | 50 | 4.4 | 1 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:59.557999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322147 | REC_0010814 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 15.2 | 67 | male | 1 | 8 | 6.5 | 7 | sotorasib 960 mg daily | 16.5 | false | MSI-H | 2026-03-15T05:35:59.558256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505333 | REC_0010815 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 16.7 | 64 | male | 1 | 23 | 6.1 | 1 | sotorasib 960 mg daily | 19.4 | true | MSI-H | 2026-03-15T05:35:59.558504+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316330 | REC_0010816 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 18.9 | 69 | male | 1 | 17 | 5 | 6 | sotorasib 960 mg daily | 10.6 | true | MSS | 2026-03-15T05:35:59.558749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231231 | REC_0010817 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 14 | 60 | male | 1 | 22 | 4.8 | 5 | alectinib 600 mg BID | 9.2 | false | MSI-H | 2026-03-15T05:35:59.559115+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215553 | REC_0010818 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.6 | 69 | male | 0 | 11 | 3.8 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.559362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773953 | REC_0010819 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.4 | 66 | male | 0 | 40 | 6.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 10 | true | MSS | 2026-03-15T05:35:59.559596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356046 | REC_0010820 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 14 | 80 | female | 1 | 21 | 4.4 | 2 | sotorasib 960 mg daily | 22.5 | false | MSI-H | 2026-03-15T05:35:59.559834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696063 | REC_0010821 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14.8 | 72 | male | 2 | 6 | 5.2 | 1 | osimertinib 80 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:59.560123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389306 | REC_0010822 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.9 | 71 | female | 1 | 44 | 6.5 | 3 | carboplatin + paclitaxel + pembrolizumab | 19.1 | true | MSS | 2026-03-15T05:35:59.560386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611004 | REC_0010823 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 9 | 67 | male | 0 | 21 | 5.7 | 1 | osimertinib 80 mg daily | 22.6 | false | MSS | 2026-03-15T05:35:59.560644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416005 | REC_0010824 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 14 | 4.6 | 63 | male | 1 | 20 | 8.5 | 2 | pembrolizumab 200 mg q3w | 13 | true | MSS | 2026-03-15T05:35:59.560905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109708 | REC_0010825 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.6 | 56 | female | 1 | 65 | 6.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:59.561174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795990 | REC_0010826 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 19.9 | 85 | male | 2 | 9 | 5 | 5 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.561505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388812 | REC_0010827 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.4 | 65 | male | 0 | 13 | 4.9 | 5 | pembrolizumab 200 mg q3w | 12.5 | false | MSS | 2026-03-15T05:35:59.561756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960728 | REC_0010828 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6 | 64 | male | 0 | 39 | 8 | 3 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:59.561994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916720 | REC_0010829 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 16.5 | 66 | female | 0 | 9 | 3.6 | 7 | osimertinib 80 mg daily | 15.2 | false | MSS | 2026-03-15T05:35:59.562231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215858 | REC_0010830 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10.2 | 82 | female | 1 | 12 | 6.3 | 6 | alectinib 600 mg BID | 10.2 | true | MSI-H | 2026-03-15T05:35:59.562573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846567 | REC_0010831 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.7 | 60 | male | 0 | 25 | 6.9 | 6 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:35:59.562816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839747 | REC_0010832 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 9 | 70 | male | 2 | 13 | 6.7 | 4 | osimertinib 80 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:59.563047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864031 | REC_0010833 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.3 | 58 | male | 1 | 23 | 4 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:35:59.563279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399657 | REC_0010834 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.8 | 69 | female | 1 | 16 | 5.6 | 2 | alectinib 600 mg BID | 21.4 | true | MSI-H | 2026-03-15T05:35:59.563515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690053 | REC_0010835 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 11.4 | 71 | female | 0 | 4 | 6.3 | 4 | osimertinib 80 mg daily | 6.6 | false | MSI-H | 2026-03-15T05:35:59.563861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_868327 | REC_0010836 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.4 | 57 | female | 1 | 49 | 4.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.8 | false | MSS | 2026-03-15T05:35:59.564366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627388 | REC_0010837 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.7 | 74 | female | 1 | 68 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.8 | true | MSS | 2026-03-15T05:35:59.564858+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167667 | REC_0010838 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 15.9 | 63 | female | 1 | 12 | 5.5 | 4 | osimertinib 80 mg daily | 4.2 | true | MSI-H | 2026-03-15T05:35:59.565100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_158025 | REC_0010839 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 31 | 4.6 | 72 | female | 1 | 71 | 4.9 | 2 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:35:59.565335+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144637 | REC_0010840 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 11.3 | 53 | female | 0 | 19 | 5.7 | 1 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:59.565572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814571 | REC_0010841 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 14 | 68 | female | 1 | 12 | 5.8 | 2 | osimertinib 80 mg daily | 12.3 | false | MSS | 2026-03-15T05:35:59.565850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643584 | REC_0010842 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 6.6 | 67 | male | 1 | 13 | 4.3 | 7 | entrectinib 600 mg daily | 10.4 | true | MSS | 2026-03-15T05:35:59.566092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400602 | REC_0010843 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 3.8 | 60 | female | 0 | 12 | 6.5 | 1 | entrectinib 600 mg daily | 24.2 | true | MSS | 2026-03-15T05:35:59.566392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389024 | REC_0010844 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 7.7 | 61 | female | 1 | 15 | 4.2 | 5 | sotorasib 960 mg daily | 14.1 | false | MSS | 2026-03-15T05:35:59.566628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757121 | REC_0010845 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.5 | 54 | female | 0 | 15 | 4.8 | 5 | osimertinib 80 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:59.566862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830023 | REC_0010846 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 10.3 | 73 | female | 2 | 43 | 5.9 | 6 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:35:59.567095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218776 | REC_0010847 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 18 | 77 | female | 2 | 27 | 4.3 | 5 | osimertinib 80 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:59.567333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749536 | REC_0010848 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 9.7 | 70 | male | 1 | 4 | 5.5 | 1 | sotorasib 960 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:59.567574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253649 | REC_0010849 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.7 | 70 | female | 1 | 72 | 6.6 | 7 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:35:59.567813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_751119 | REC_0010850 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.2 | 71 | female | 1 | 16 | 6.9 | 5 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:35:59.568044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219297 | REC_0010851 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 6.2 | 78 | female | 1 | 11 | 4.8 | 1 | pembrolizumab 200 mg q3w | 20.1 | false | MSS | 2026-03-15T05:35:59.568312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271558 | REC_0010852 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 4.7 | 67 | female | 0 | 70 | 5.5 | 2 | pembrolizumab 200 mg q3w | 24.8 | true | MSS | 2026-03-15T05:35:59.568558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255011 | REC_0010853 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 9.6 | 71 | male | 1 | 22 | 6.6 | 4 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:59.568803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512409 | REC_0010854 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 11.9 | 72 | female | 2 | 15 | 6 | 1 | sotorasib 960 mg daily | 13.4 | false | MSI-H | 2026-03-15T05:35:59.569049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241206 | REC_0010855 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.6 | 70 | female | 2 | 42 | 6.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.4 | false | MSS | 2026-03-15T05:35:59.569311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280398 | REC_0010856 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.6 | 80 | male | 3 | 13 | 5 | 3 | osimertinib 80 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:59.569735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153931 | REC_0010857 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 13 | 80 | male | 1 | 17 | 6.1 | 2 | osimertinib 80 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:59.570068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_362758 | REC_0010858 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.8 | 77 | female | 1 | 12 | 4.1 | 7 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.570415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553915 | REC_0010859 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.2 | 63 | female | 1 | 6 | 5.5 | 6 | pembrolizumab 200 mg q3w | 7.9 | false | MSS | 2026-03-15T05:35:59.570676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223072 | REC_0010860 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.2 | 70 | male | 2 | 17 | 5.2 | 8 | pembrolizumab 200 mg q3w | 4.5 | false | MSS | 2026-03-15T05:35:59.570931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370717 | REC_0010861 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 9.8 | 74 | female | 2 | 12 | 7.4 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.571190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358731 | REC_0010862 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.7 | 60 | male | 0 | 12 | 5.9 | 2 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:59.571460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328707 | REC_0010863 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 15.1 | 62 | female | 1 | 11 | 8 | 6 | sotorasib 960 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:59.571725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133554 | REC_0010864 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.1 | 78 | female | 1 | 19 | 6 | 1 | entrectinib 600 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:59.571966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450284 | REC_0010865 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 13 | 70 | female | 2 | 16 | 5.2 | 8 | alectinib 600 mg BID | 17.1 | false | MSI-H | 2026-03-15T05:35:59.572250+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565586 | REC_0010866 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 13.2 | 68 | female | 0 | 12 | 5.3 | 2 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:35:59.572513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189599 | REC_0010867 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 12.4 | 57 | female | 0 | 8 | 4.3 | 2 | alectinib 600 mg BID | 16.4 | true | MSI-H | 2026-03-15T05:35:59.572770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_250737 | REC_0010868 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 16.2 | 56 | male | 1 | 10 | 5.1 | 1 | sotorasib 960 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:35:59.573008+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381763 | REC_0010869 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 3.2 | 67 | female | 1 | 19 | 7.5 | 2 | osimertinib 80 mg daily | 16.3 | true | MSS | 2026-03-15T05:35:59.573359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952309 | REC_0010870 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 16 | 61 | female | 0 | 9 | 6.9 | 2 | sotorasib 960 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:59.573626+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366494 | REC_0010871 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 5.9 | 54 | male | 0 | 31 | 6.1 | 5 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:35:59.573920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_942494 | REC_0010872 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 4.4 | 67 | female | 1 | 5 | 5.6 | 4 | entrectinib 600 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.574323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392487 | REC_0010873 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.8 | 85 | female | 0 | 9 | 5.5 | 7 | entrectinib 600 mg daily | 9.3 | false | MSI-H | 2026-03-15T05:35:59.574584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680373 | REC_0010874 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 8.5 | 65 | female | 1 | 14 | 5 | 1 | osimertinib 80 mg daily | 20.9 | true | MSS | 2026-03-15T05:35:59.574846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783429 | REC_0010875 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.7 | 61 | male | 0 | 39 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 14.9 | true | MSS | 2026-03-15T05:35:59.575135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198151 | REC_0010876 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.5 | 63 | female | 0 | 65 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.9 | false | MSS | 2026-03-15T05:35:59.575406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804072 | REC_0010877 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 2.3 | 60 | male | 1 | 14 | 6.2 | 7 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:59.575673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_188968 | REC_0010878 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 6.6 | 80 | female | 2 | 18 | 5.2 | 6 | osimertinib 80 mg daily | 11.7 | false | MSS | 2026-03-15T05:35:59.575949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376868 | REC_0010879 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.9 | 65 | male | 1 | 12 | 4.7 | 8 | entrectinib 600 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:59.576293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411591 | REC_0010880 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.2 | 66 | female | 0 | 12 | 3.4 | 8 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:35:59.576622+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237104 | REC_0010881 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 8.4 | 67 | female | 0 | 10 | 5.4 | 7 | entrectinib 600 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:59.576909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352919 | REC_0010882 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 4.8 | 70 | female | 3 | 43 | 4.8 | 2 | pembrolizumab 200 mg q3w | 12.3 | true | MSS | 2026-03-15T05:35:59.577332+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754629 | REC_0010883 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 16.9 | 64 | male | 0 | 23 | 4.9 | 7 | osimertinib 80 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:59.577594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225154 | REC_0010884 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4.5 | 85 | female | 2 | 27 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.1 | true | MSS | 2026-03-15T05:35:59.577838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_253265 | REC_0010885 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 19.8 | 67 | female | 0 | 12 | 6.8 | 2 | sotorasib 960 mg daily | 24.1 | true | MSI-H | 2026-03-15T05:35:59.578082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775268 | REC_0010886 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 18 | 7.7 | 69 | female | 1 | 20 | 4.5 | 5 | pembrolizumab 200 mg q3w | 19 | false | MSS | 2026-03-15T05:35:59.578319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_767701 | REC_0010887 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 12.6 | 69 | female | 0 | 21 | 4.9 | 4 | osimertinib 80 mg daily | 16.4 | true | MSS | 2026-03-15T05:35:59.578556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267315 | REC_0010888 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 15 | 65 | male | 0 | 9 | 3.7 | 3 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:59.578812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210665 | REC_0010889 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 10.7 | 58 | female | 0 | 19 | 3.1 | 2 | alectinib 600 mg BID | 29.4 | false | MSI-H | 2026-03-15T05:35:59.579215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949428 | REC_0010890 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 4.5 | 68 | female | 1 | 42 | 5.7 | 6 | pembrolizumab 200 mg q3w | 6.9 | false | MSS | 2026-03-15T05:35:59.579492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604374 | REC_0010891 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 11.1 | 74 | female | 0 | 16 | 6.7 | 1 | entrectinib 600 mg daily | 21.8 | false | MSI-H | 2026-03-15T05:35:59.579769+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648517 | REC_0010892 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 3.3 | 61 | female | 1 | 12 | 4.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:35:59.580056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487747 | REC_0010893 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 5.4 | 81 | female | 2 | 54 | 5.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.5 | false | MSS | 2026-03-15T05:35:59.580435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162337 | REC_0010894 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 11.5 | 69 | male | 1 | 17 | 5.4 | 0 | osimertinib 80 mg daily | 50.5 | true | MSS | 2026-03-15T05:35:59.580750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_803262 | REC_0010895 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 12.2 | 58 | male | 1 | 10 | 5.3 | 1 | osimertinib 80 mg daily | 17.9 | true | MSS | 2026-03-15T05:35:59.581163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662772 | REC_0010896 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 4.6 | 47 | male | 0 | 57 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:59.581435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_643062 | REC_0010897 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 12.5 | 67 | male | 1 | 17 | 6.8 | 2 | osimertinib 80 mg daily | 18.2 | false | MSI-H | 2026-03-15T05:35:59.581687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481467 | REC_0010898 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 16.3 | 74 | female | 1 | 21 | 3.6 | 2 | osimertinib 80 mg daily | 6.8 | true | MSI-H | 2026-03-15T05:35:59.581933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460987 | REC_0010899 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 11.3 | 76 | female | 2 | 31 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.9 | false | MSI-H | 2026-03-15T05:35:59.582180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967099 | REC_0010900 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.7 | 67 | female | 1 | 16 | 3.9 | 1 | entrectinib 600 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:59.582426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.